Combined, these data support somatic expansion of the CAG repeat as a novel therapeutic target in HD, and likely in other repeat expansion disorders, reveal a potential peripheral biomarker of somatic expansion for clinical trials, and highlight FAN1, MLH1, MSH3 and MLH3 as potential drug targets. This evidence concerns the gene MLH3 and Huntington disease.